Tiziana Life Sciences Reports Six-Month Qualitative Results For All 10 Non-Active Secondary Progressive Multiple Sclerosis Patients Enrolled In Intermediate-Size Patient Population Expanded Access Program
Portfolio Pulse from Benzinga Newsdesk
Tiziana Life Sciences reported six-month qualitative results for 10 non-active Secondary Progressive Multiple Sclerosis (na-SPMS) patients in their Expanded Access Program. 80% of patients showed improvements in PET imaging. The FDA has allowed an additional 20 patients to be enrolled, and Tiziana has applied for FDA Orphan Drug Designation for foralumab.
June 06, 2024 | 1:09 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Tiziana Life Sciences reported positive six-month results for na-SPMS patients, with 80% showing improvements. The FDA has allowed more patients to be enrolled and Tiziana has applied for Orphan Drug Designation for foralumab.
The positive results and FDA's allowance for more patients indicate strong potential for foralumab, which could lead to increased investor confidence and a potential rise in stock price. The application for Orphan Drug Designation further adds to the positive outlook.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100